IGC 파머 (IGC) 주가

IGC 파머(IGC)는 AMX에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.29 (+6.98%), 시가총액 $27.76M, 52주 범위 $0.25 ~ $0.47.

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's. Its pre-clinical stage product candidate includes TGR-63 and IGC-M3 to treat Alzheimer's disease. In addition, the company develops MINT-AD, an AI-driven assistant for healthcare providers. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. IGC Pharma, Inc.

핵심 지표

• 현재가: $0.29 (+6.98%)
• 시가총액: $27.76M
• 52주 최저~최고: $0.25 ~ $0.47
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: AMX

IGC 파머의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.

IGC 파머 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 적극 매수 (5.0 / 5)

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 3.75
• 순이익률: 0.00%
• 영업이익률: -775.39%

자주 묻는 질문